Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race

Partnership Seen As Validating CD70 As Antigen Target

The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.

3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration — The deal between Nkarta and CRISPR includes CD70 plus an undetermined target • Source: Shutterstock

The development and commercialization partnership that Nkarta, Inc. announced with CRISPR Therapeutics AG could help make Nkarta a bigger player in the natural killer (NK) cell therapy space, and also gives further validation to CD70 as an antigen target in hematology-oncology.

South San Francisco, CA-based Nkarta and Zug, Switzerland-based CRISPR announced the deal on 6 May, which will focus on the CD70 tumor antigen target and an additional target that remains undetermined, along with plans to develop a combined NK- and T-cell therapy candidate

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

06 May 2025

• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

05 May 2025

• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

In Brief: Sanofi Gains €10bn From Opella Sale

02 May 2025

• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.